Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 3/2017

03.11.2016 | Original Article – Clinical Oncology

Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye

verfasst von: Andrea Papadia, Ignacio Zapardiel, Beatrice Bussi, Fabio Ghezzi, Marcello Ceccaroni, Elena De Ponti, Federica Elisei, Sara Imboden, Begoña Diaz de la Noval, Maria Luisa Gasparri, Giampaolo Di Martino, Javier De Santiago, Michael Mueller, Francesca Vecchione, Federica Dell’Orto, Alessandro Buda

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to compare technetium radiocolloid (Tc99m) + blue dye (BD) versus Indocyanine green (ICG) fluorescent dye in terms of the overall detection rate and bilateral sentinel lymph node (SLN) mapping in patients with endometrial carcinoma.

Methods

Patients from five European centers with apparently confined clinical stage I endometrial cancer were reviewed. A comparison was made between women who received SLN mapping with pelvic and/or aortic lymphadenectomy (LND), and women who underwent SLN algorithm (SA), was also performed between the two groups.

Results

Three hundred and forty-two (342) women were involved (147 in the Tc99m + BD group and 195 in the ICG group). The overall detection rate of SLN biopsy was 97.3% (143/147) for women in the Tc99m + BD group and 96.9% (189/195) for women in the ICG group (p = 0.547). The bilateral mapping rate for ICG was 84.1%—significantly higher with respect to the 73.5% obtained with Tc99m + BD (p = 0.007). No differences in overall sensitivity (OS) and overall false negative rate (FNR) were seen between LND and SA (p value = 0.311), whereas the negative predictive value (NPV) was in favor of SA group (p value = 0.030).

Conclusions

In this study, fluorescent mapping using ICG resulted equivalent to the standard combined radiocolloid and BD, but real-time SLN mapping achieves a higher bilateral detection rate. The added value that this fast emerging technology promises to give certainly warrants future studies to further consolidate the advantages there are over the standard technique.
Literatur
Zurück zum Zitat AlHilli MM, Mariani A (2014) Preoperative selection of endometrial cancer patients at low risk for lymph node metastases: useful criteria for enrollment in clinical trials. J Gynecol Oncol 25:267–269CrossRefPubMedPubMedCentral AlHilli MM, Mariani A (2014) Preoperative selection of endometrial cancer patients at low risk for lymph node metastases: useful criteria for enrollment in clinical trials. J Gynecol Oncol 25:267–269CrossRefPubMedPubMedCentral
Zurück zum Zitat Barlin JN, Khoury-Collado F, Kim CH, Leitao MM, Chi DS et al (2012) The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 125(3):531–535CrossRefPubMed Barlin JN, Khoury-Collado F, Kim CH, Leitao MM, Chi DS et al (2012) The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 125(3):531–535CrossRefPubMed
Zurück zum Zitat Buda A, Crivellaro C, Elisei F, Di Martino G, Guerra L, De Ponti E et al (2016a) Impact of indocyanine green for sentinel lymph node mapping in early stage endometrial and cervical cancer: comparison with conventional radiotracer (99 m) Tc and/or blue dye. Ann Surg Oncol 23:2183–2191CrossRefPubMed Buda A, Crivellaro C, Elisei F, Di Martino G, Guerra L, De Ponti E et al (2016a) Impact of indocyanine green for sentinel lymph node mapping in early stage endometrial and cervical cancer: comparison with conventional radiotracer (99 m) Tc and/or blue dye. Ann Surg Oncol 23:2183–2191CrossRefPubMed
Zurück zum Zitat Buda A, Elisei F, Palazzi S, De Ponti E, Arosio M, Vecchione F et al (2016b) Quality of care for cervical and endometrial cancer patients: the impact of different techniques of sentinel lymph node mapping on patient satisfaction. Ann Surg Oncol 23(9):2975–2981CrossRefPubMed Buda A, Elisei F, Palazzi S, De Ponti E, Arosio M, Vecchione F et al (2016b) Quality of care for cervical and endometrial cancer patients: the impact of different techniques of sentinel lymph node mapping on patient satisfaction. Ann Surg Oncol 23(9):2975–2981CrossRefPubMed
Zurück zum Zitat Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J et al (2016) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol 27:16–41CrossRefPubMed Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J et al (2016) ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol 27:16–41CrossRefPubMed
Zurück zum Zitat Cormier B, Rozenholc AT, Gotlieb W, Plante M, Giede C (2015) Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol 138:478–485CrossRefPubMed Cormier B, Rozenholc AT, Gotlieb W, Plante M, Giede C (2015) Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol 138:478–485CrossRefPubMed
Zurück zum Zitat Derai E, Dubernard G, Bats AS (2015) Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol 136:54–59CrossRef Derai E, Dubernard G, Bats AS (2015) Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol 136:54–59CrossRef
Zurück zum Zitat Handgraaf HJ, Verbeek FP, Tummers QR, Boogerd LS, van de Velde CJ, Vahrmeijer AL et al (2014) Real-time near-infrared fluorescence guided surgery in gynecologic oncology: a review of the current state of the art. Gynecol Oncol 135(3):606–613CrossRefPubMed Handgraaf HJ, Verbeek FP, Tummers QR, Boogerd LS, van de Velde CJ, Vahrmeijer AL et al (2014) Real-time near-infrared fluorescence guided surgery in gynecologic oncology: a review of the current state of the art. Gynecol Oncol 135(3):606–613CrossRefPubMed
Zurück zum Zitat How J, Gotlieb WH, Press ZJ, Abitbol J, Pelmus M, Ferenczy A et al (2015) Comparing indocyanine gree, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. Gynecol Oncol 137(3):436–442CrossRefPubMed How J, Gotlieb WH, Press ZJ, Abitbol J, Pelmus M, Ferenczy A et al (2015) Comparing indocyanine gree, technetium, and blue dye for sentinel lymph node mapping in endometrial cancer. Gynecol Oncol 137(3):436–442CrossRefPubMed
Zurück zum Zitat Huynh KT, Bilchik AJ (2015) Sentinel lymph node biopsy and nodal ultrastaging in colorectal cancer. Cancer J 21:11–16CrossRefPubMed Huynh KT, Bilchik AJ (2015) Sentinel lymph node biopsy and nodal ultrastaging in colorectal cancer. Cancer J 21:11–16CrossRefPubMed
Zurück zum Zitat Jewell EL, Huang JJ, Abu-Rustum NR, Gardner GJ, Brown CL, Sonoda Y et al (2014) Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. Gynecol Oncol 133(2):274–277CrossRefPubMed Jewell EL, Huang JJ, Abu-Rustum NR, Gardner GJ, Brown CL, Sonoda Y et al (2014) Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. Gynecol Oncol 133(2):274–277CrossRefPubMed
Zurück zum Zitat Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136CrossRefPubMed Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136CrossRefPubMed
Zurück zum Zitat Kumar S, Podratz KC, Bakkum-Gamez JN, Dowdy SC, Waever AL, McGree ME et al (2014) Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol 132:38–43CrossRefPubMed Kumar S, Podratz KC, Bakkum-Gamez JN, Dowdy SC, Waever AL, McGree ME et al (2014) Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol 132:38–43CrossRefPubMed
Zurück zum Zitat Panici PB, Basile S, Maneschi F, Lissoni A, Signorelli M, Scambia G et al (2008) Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716CrossRef Panici PB, Basile S, Maneschi F, Lissoni A, Signorelli M, Scambia G et al (2008) Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716CrossRef
Zurück zum Zitat Porcu E, Salis A, Gavini E, Rassu G, Maestri M, Giunchedi P (2016) Indocyanine green delivery systems for tumour detection and treatments. Biotechnol Adv 34:768–789CrossRefPubMed Porcu E, Salis A, Gavini E, Rassu G, Maestri M, Giunchedi P (2016) Indocyanine green delivery systems for tumour detection and treatments. Biotechnol Adv 34:768–789CrossRefPubMed
Zurück zum Zitat Pronin SM, Novikova OV, Andreeva JY, Novikova EG (2015) Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer 25:1010–1014CrossRefPubMed Pronin SM, Novikova OV, Andreeva JY, Novikova EG (2015) Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer 25:1010–1014CrossRefPubMed
Zurück zum Zitat Ruscito I, Gasparri ML, Braicu EI, Bellati F, Raio L et al (2016) Sentinel node mapping in cervical cancer and endometrial cancer: indocyanine green versus other conventional dyes- a meta-analysis. Ann Surg Oncol 23(11):3749–3756CrossRefPubMed Ruscito I, Gasparri ML, Braicu EI, Bellati F, Raio L et al (2016) Sentinel node mapping in cervical cancer and endometrial cancer: indocyanine green versus other conventional dyes- a meta-analysis. Ann Surg Oncol 23(11):3749–3756CrossRefPubMed
Zurück zum Zitat Sinno AK, Fader AN, Roche KL, Giuntoli RL, Tanner EJ (2014) A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer. Gynecol Oncol 134:281–286CrossRefPubMed Sinno AK, Fader AN, Roche KL, Giuntoli RL, Tanner EJ (2014) A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer. Gynecol Oncol 134:281–286CrossRefPubMed
Zurück zum Zitat Takeuchi H, Kitagawa Y (2015) Sentinel lymph node biopsy in gastric cancer. Cancer J 21:21–24CrossRefPubMed Takeuchi H, Kitagawa Y (2015) Sentinel lymph node biopsy in gastric cancer. Cancer J 21:21–24CrossRefPubMed
Zurück zum Zitat Zahl Eriksson AG, Ducie J, Ali N, McGree ME, Waever AL, Bogani G et al (2016) Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecol Oncol 140:394–399CrossRefPubMed Zahl Eriksson AG, Ducie J, Ali N, McGree ME, Waever AL, Bogani G et al (2016) Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecol Oncol 140:394–399CrossRefPubMed
Metadaten
Titel
Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye
verfasst von
Andrea Papadia
Ignacio Zapardiel
Beatrice Bussi
Fabio Ghezzi
Marcello Ceccaroni
Elena De Ponti
Federica Elisei
Sara Imboden
Begoña Diaz de la Noval
Maria Luisa Gasparri
Giampaolo Di Martino
Javier De Santiago
Michael Mueller
Francesca Vecchione
Federica Dell’Orto
Alessandro Buda
Publikationsdatum
03.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2297-y

Weitere Artikel der Ausgabe 3/2017

Journal of Cancer Research and Clinical Oncology 3/2017 Zur Ausgabe

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.